Andrew Green Sells 6,510 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) SVP Andrew Green sold 6,510 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $27.27, for a total transaction of $177,527.70. Following the completion of the sale, the senior vice president directly owned 53,133 shares in the company, valued at $1,448,936.91. This trade represents a 10.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Artivion Trading Down 0.0%

NYSE AORT traded down $0.01 on Friday, reaching $25.61. The stock had a trading volume of 139,212 shares, compared to its average volume of 597,321. The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82. The stock has a fifty day moving average price of $26.05 and a two-hundred day moving average price of $29.23. Artivion, Inc. has a 12-month low of $19.16 and a 12-month high of $48.25. The firm has a market capitalization of $1.25 billion, a price-to-earnings ratio of -365.49 and a beta of 1.25.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%.The firm had revenue of $125.76 million for the quarter, compared to the consensus estimate of $119.99 million. As a group, sell-side analysts forecast that Artivion, Inc. will post 0.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd acquired a new position in shares of Artivion in the 3rd quarter valued at $27,000. Rockefeller Capital Management L.P. grew its holdings in shares of Artivion by 150.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after buying an additional 399 shares during the last quarter. Larson Financial Group LLC raised its stake in Artivion by 148.5% during the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after acquiring an additional 563 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Artivion by 47.7% in the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after purchasing an additional 538 shares during the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new position in Artivion during the 4th quarter worth $79,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on AORT shares. Citigroup restated a “market outperform” rating on shares of Artivion in a report on Tuesday, July 21st. Citizens Jmp decreased their price target on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a research report on Friday, May 8th. Canaccord Genuity Group boosted their price target on shares of Artivion from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Needham & Company LLC reaffirmed a “buy” rating and set a $44.00 price objective on shares of Artivion in a research report on Monday, July 20th. Finally, Stifel Nicolaus set a $45.00 price objective on shares of Artivion in a research report on Monday, June 1st. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Artivion currently has a consensus rating of “Moderate Buy” and an average price target of $44.83.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.